Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human TTX-381 for ocular manifestations of CLN2 disease
2025-521175-31-00Phase 2Authorised
- Sponsor
- Tern Therapeutics
- Start
- Jul 2025
- Modality
- Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of RGX-381 in neuronal ceroid lipofuscinosis type 2 (CLN2), sponsored by Tern Therapeutics. Primary endpoint: Ocular and overall adverse events and serious adverse events through Day 360. Planned start Jul 2025; status: authorised.
02
Drugs
RGX-381
03
Conditions
neuronal ceroid lipofuscinosis type 2 (CLN2)
Beyond the preview
Go deeper on 2025-521175-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521175-31-00.